Clinical Trial: Propionic Acid for Multiple Sclerosis: Safety and Benefits

U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07595081) titled 'Propionic Acid for Multiple Sclerosis: Safety and Benefits' on May 03.

Brief Summary: The purpose of this study is to explore the long-term safety, tolerability, and clinical efficacy of propionic acid as an add-on therapy in multiple sclerosis (MS).

Study Start Date: Aug. 01, 2024

Study Type: INTERVENTIONAL

Condition: Multiple Sclerosis

Intervention: DIETARY_SUPPLEMENT: Propionic acid 1000 mg capsule

Patients will receive propionic acid as add on MS treatment.

Recruitment Status: COMPLETED

Sponsor: Salzburger Landeskliniken

Information provided by (Responsible Party): Tobias Moser, Salzburger Landeskliniken

Published by H...